Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and AT-101 in Advanced NSCLC
NCT00988169Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2009
- Primary completion
- May 2010
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of r-(-)-gossypol acetic acid in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2009; status: terminated.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00988169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00988169.